The ASCO Post
A new four-drug therapy called Smart Stop was presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. Investigators reported this targeted therapy is promising for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Dipenkumar Modi, M.D., hematologist and medical oncologist, and member of the Bone Marrow & Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, reviewed the study and agrees that Smart Stop could be a safe and effective therapeutic approach with positive results over the next year or so.
Read the article here.